> Details

Schetelig, Johannes; Bornhäuser, Martin; Schmid, Christoph; Hertenstein, Bernd; Schwerdtfeger, Rainer; Martin, Hans; Stelljes, Matthias; Hegenbart, Ute; Schäfer-Eckart, Kerstin; Füssel, Monika; Wiedemann, Barbel; Thiede, Christian; Kienast, Joachim; Baurmann, Herrad; Ganser, Arnold; Kolb, Hans Jochem; Ehninger, Gerhard

Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
  • Contributor: Schetelig, Johannes; Bornhäuser, Martin; Schmid, Christoph; Hertenstein, Bernd; Schwerdtfeger, Rainer; Martin, Hans; Stelljes, Matthias; Hegenbart, Ute; Schäfer-Eckart, Kerstin; Füssel, Monika; Wiedemann, Barbel; Thiede, Christian; Kienast, Joachim; Baurmann, Herrad; Ganser, Arnold; Kolb, Hans Jochem; Ehninger, Gerhard
  • imprint: American Society of Clinical Oncology (ASCO), 2008
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2007.15.5184
  • ISSN: 0732-183X; 1527-7755
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Purpose</jats:title><jats:p> In patients with acute myeloid leukemia (AML), differential indications for matched sibling and unrelated hematopoietic stem-cell transplantation (HCT) are considered, and arbitrary age limits for HCT exist. We sought to determine whether donor type is a prognostic factor in elderly patients in the era of high-resolution DNA-based HLA typing. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed univariate and multivariate analyses of event-free survival (EFS) and overall survival (OS) in patients older than 50 years with standard- or high-risk AML who had received an allogeneic HCT between 1995 and 2005. Available DNA from donors and recipients of unrelated HCT was retyped so that the HLA-A, -B, -C, and -DRB1 alleles could be characterized in detail. Unrelated donors (UDs) were classified as matched (8/8), possibly matched (matched, but incomplete information), partially matched (one mismatch), or poorly matched (two or more mismatches) according to the final typing results. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Data from 368 patients with a median age of 57 years (range, 50 to 73 years) were included. Multivariate Cox regression analysis revealed that patients’ disease status at HCT (P &lt; .001) and the cytogenetic risk (P &lt; .001) highly significantly predicted EFS and OS. Compared with patients with matched sibling donors, the adjusted relative risk of EFS was 0.7 (95% CI, 0.4 to 1.1) for patients with matched UDs and 1.0 (95% CI, 0.7 to 1.6) for patients with partially matched UDs. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Donor type is not a major prognostic factor for HCT in elderly patients with standard- or high-risk AML. </jats:p></jats:sec>
  • Access State: Open Access